Clarus Ventures has raised $789.7 million to date for its Clarus IV, per a SEC filing. The Cambridge-headquartered firm has set a $880 million target and began fundraising in 2017. The SEC filing did not disclose whether the capital raise constituted a final or interim close.
Its previous fund raised $500 million in 2015.
The fund will target venture capital opportunities in pharmaceutical and biotech sectors in North America.